摘要
目的观察抗苗勒氏管激素(AMH)和卵泡刺激素(FSH)对多囊卵巢综合征(PCOS)的诊断效能。方法将本院PCOS患者80例作为试验组,同期选取体检健康女性80例作为对照组,检测所有受试者的AMH、FSH水平。结果试验组与对照组AMH分别为(9.36±1.02)和(3.68±0.50)ng·m L^-1,FSH分别为(5.52±0.58)和(6.51±0.71)U·L^-1,差异均有统计学意义(均P<0.05)。试验组中,肥胖、稀少或无排卵、高雄激素血症(HA)、卵巢多囊样改变(PCOM)、胰岛素抵抗(IR)患者AMH明显高于无上述症状患者,有上述症状患者FSH明显低于无上述症状患者,差异均有统计学意义(均P<0.05)。ROC曲线分析显示,在诊断PCOS敏感度、特异度、准确度中,AMH>6.5 ng·m L^-1时为87.50%,80.00%,83.50%,FSH<6.0 U·L^-1时为77.50%,67.50%,72.50%,AMH和FSH联合时为97.50%,95.00%,96.25%,差异有统计学意义(P<0.05)。结论AMH、FSH与PCOS的发生发展有关,PCOS患者以AMH升高、FSH下降为特征,二者对PCOS具有良好的诊断效能,且二者联合时的效能更高。
Objective To discuss the diagnostic efficacy of antimullerian hormone(AMH)and follicle stimulating hormone(FSH)in polycystic ovary syndrome(PCOS).Methods Eighty patients with PCOS were selected as treatment group in our hospital,80 healthy women were selected as control group at the same time.All volunteers were tested the AMH and FSH.Results The AMH in treatment group and control group were(9.36±1.02)and(3.68±0.50)ng·m L^-1,the FSH were(5.52±0.58)and(6.51±0.71)U·L^-1,the difference was statistically significant(P<0.05).In treatment group,the AMH in patients with obesity,sparse or anovulation,hyperandrogenism(HA),polycystic ovarian change(PCOM),insulin resistance(IR)were significantly higher than that in patients without the above symptoms,the FSH in patients with the above symptoms were significantly lower than that in patients without the above symptoms,the difference was statistically significant(P<0.05).The ROC analysis showed that,in the sensitivity,specificity,accuracy of diagnosis of PCOS,the AMH>6.5 ng·m L^-1 were 87.50%,80.00%,83.50%,the FSH<6.0 U·L^-1 were77.50%,67.50%,72.50%,the AMH combined FSH were 97.50%,95.00%,96.25%,the difference was statistically significant(P<0.05).Conclusion AMH and FSH are related to the occurrence and development of PCOS,PCOS patients are characterized by the increase in AMH and decrease in FSH,and both of them have the good diagnostic efficacy for PCOS,and their combination is more effective.
作者
范芸
解娟
施瑞洁
刘尧
FAN Yun;XIE Juan;SHI Rui-jie;LIU Yao(Clinical Laboratory,Shaanxi Provincial People’s Hospital,Xi’an 710068,Shaanxi Province,China;Clinical Laboratory,Huashan Central Hospital of Xi’an,Xi’)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2019年第21期2665-2667,共3页
The Chinese Journal of Clinical Pharmacology
关键词
抗苗勒氏管激素
卵泡刺激素
多囊卵巢综合征
诊断效能
antimullerian hormone
follicle stimulating hormone
polycystic ovary syndrome
diagnostic efficacy
